Analyst Ratings February 12, 2026

Rothschild Redburn Lowers Legend Biotech Rating, Cites Competitive Pressure on Carvykti

Analyst trims price target sharply after ASH 2025 survey flags competing bispecific therapies; mixed analyst reactions follow a sales miss

By Ajmal Hussain LEGN
Rothschild Redburn Lowers Legend Biotech Rating, Cites Competitive Pressure on Carvykti
LEGN

Rothschild Redburn reduced its rating on Legend Biotech (LEGN) from Buy to Neutral and cut the firm's price target from $83.00 to $24.00 after identifying competitive risks to Carvykti at ASH 2025. The firm also trimmed its peak sales forecast for the drug to about $6 billion from roughly $10 billion. Other analysts have reacted with a range of adjustments following a reported sales shortfall for CARVYKTI.

Key Points

  • Rothschild Redburn downgraded Legend Biotech from Buy to Neutral and cut its price target to $24.00 from $83.00, citing competitive pressures for Carvykti.
  • The firm reduced its global peak sales estimate for Carvykti to about $6 billion from roughly $10 billion, placing its forecast about 16% below consensus.
  • Other analysts reacted to a CARVYKTI sales miss of $555 million versus a $582 million consensus with mixed actions: some trimmed targets and ratings while others upheld positive views based on regulatory guidance and upcoming clinical milestones.

Rothschild Redburn announced a downgrade for Legend Biotech Corp. (NASDAQ:LEGN), moving its recommendation from Buy to Neutral and dropping its price target to $24.00 from $83.00. The change follows observations made around the ASH 2025 conference, where the research house flagged intensifying competition for Carvykti, Legend’s sole marketed therapy for multiple myeloma.

The stock was trading at $18.54 at the time of the report. That price represents an 11% rebound over the last week, despite a near 50% decline during the prior six months.

Rothschild Redburn pointed to findings from its proprietary survey as central to its revised outlook. The survey indicated meaningful physician interest in adopting bispecific-based therapies earlier in treatment lines for multiple myeloma, a dynamic the research house said could erode Carvykti’s market position across multiple settings.

As a result of these competitive concerns, Rothschild Redburn substantially lowered its global peak sales projection for Carvykti to approximately $6 billion, down from about $10 billion previously. The firm noted that this updated peak sales estimate sits roughly 16% beneath consensus expectations.

Analyst Qize Ding at Rothschild Redburn attributed the rating change and the steep reduction in the price target primarily to the altered view on Carvykti’s competitiveness.


Legend Biotech’s recent reported performance also factored into analyst activity across the sector. The company disclosed fourth-quarter 2025 net trade sales for CARVYKTI of $555 million, which missed the consensus estimate of $582 million. The sales shortfall prompted at least three notable analyst responses.

  • H.C. Wainwright lowered its price target for Legend Biotech from $60.00 to $50.00 but retained a Buy rating.
  • TD Cowen moved its recommendation from Buy to Hold and reduced its price target substantially, from $62.00 to $21.00, citing the sales miss.
  • Raymond James maintained an Outperform rating with a $86.00 price target, pointing to regulatory developments - specifically an FDA draft guidance that supports accelerated approval endpoints for multiple myeloma therapies - which the firm said could favor Legend’s Phase 3 CARTITUDE-6 trial and potentially accelerate approval timelines.

Deutsche Bank likewise kept a Buy rating and a $60.00 price target, highlighting upcoming clinical catalysts as positive milestones to watch, including the expected release of first patient data for an in-vivo CAR T program by the end of 2026.

The cluster of analyst moves illustrates a mixed response to recent data and competitive signals: several firms pared estimates or lowered targets in response to the sales miss and competitive survey findings, while others retained more optimistic stances tied to regulatory guidance and pending clinical readouts.

Risks

  • Increased adoption of bispecific-based therapies in earlier treatment lines could reduce Carvykti’s addressable market - impacts biotech and oncology drug markets.
  • CARVYKTI’s sales shortfall relative to consensus introduces revenue execution risk for Legend Biotech - impacts healthcare equities and revenue-dependent valuation models.
  • Clinical and regulatory outcomes remain uncertain; approval timelines and trial readouts (including Phase 3 CARTITUDE-6 and in-vivo CAR T first patient data) will materially affect sentiment - impacts biotech investment and clinical-stage program valuations.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026